Edding Genor Group (6998 HK)

Analysis

Health Care • China

Edding Genor Group is an integrated specialty biopharmaceutical company focused on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. It discovers, develops, manufactures, and commercializes biopharmaceutical products, primarily through acquiring branded drug assets and licensing patented drugs. The company is headquartered in Shanghai, China, and was founded in 2001.

Refresh

Exchange Announcement • 14 Oct 2026 21:54

Next Day Disclosure Return

Exchange Announcement • 12 Oct 2026 18:45

Next Day Disclosure Return

Exchange Announcement • 11 Oct 2026 18:11

Voluntary Announcement - Ind Approval From The Nmpa For Phase Ii Clinical Trial Of Gb268 In Colorectal Cancer

Exchange Announcement • 08 Oct 2026 18:17

Next Day Disclosure Return

Exchange Announcement • 30 Sep 2026 17:14

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00